Get all your news in one place.

100's of premium titles.
One app.

Get all your news in one place.

100's of premium titles. One news app.

INSANE: Takeda | Vintage Vibes

Takeda Pharmaceutical Q4 Earnings Call Highlights

Takeda Pharmaceutical (NYSE:TAK) reported fiscal 2025 results that management described as solid despite pressure from generic competition to VYVANSE, while outlining a transition plan built around three expected product launches and a broader cost transformation program. The earnings call also mar

MarketBeat

5 ‘Outstanding’ Kitchen Knives That This Michelin-Starred Chef Would Actually Recommend — They “Combine Design Elegance With Exceptional Function”

"A chef's knife is the heartbeat of my kitchen," says Petros Dimas, Domes Resorts executive chef and Makris Restaurants chef patron. Here are some standouts you can count on for precision, balance, and responsiveness

Livingetc

Takeda Taps Nabla Bio's Generative AI Platform For Antibody Design In $1 Billion Pact

Nabla Bio, a biotechnology company focused on de novo therapeutics design using generative AI, announced a new, multi-year research collaboration on Tuesday with Takeda Pharmaceutical Co., Ltd. (NYSE:TAK).

Benzinga

From analysis to the latest developments in health,
read the most diverse news in one place.

What's Going On With Takeda Stock On Friday?

On Friday, Takeda Pharmaceutical Co Ltd's (NYSE:TAK) stock wobbled after touching as low as $14.53 during the premarket session, before bouncing back to about $15.47 at last check Friday.

Benzinga

Takeda Pharma Maintains Outlook Even As Vyvanse Generics Hit Sales

Takeda Pharmaceutical Company Limited (NYSE:TAK) posted a strong first-quarter performance for 2025 on Wednesday, with a net profit of 124.2 billion Japanese yen (approximately $834.08 million), reflecting a notable 30.4% year-over-year increase.

Benzinga

In an uncertain world, CEOs seek growth while bracing for disruption

CEOs emphasize the need to stay nimble and rethink supply chains as barriers to trade are erected in an increasingly multipolar world.

Fortune

Why Takeda no longer has an 'IT department' as part of the drug maker's digital and data transformation

Gabriele Ricci, chief data and technology officer, has been reorganizing the technology function at Takeda Pharmaceutical.

Fortune

Read news from The Economist, FT, and more,
with one subscription

‘If they don’t get care, they die’: the woman who runs the world’s largest kidney dialysis company

Helen Giza of FME is excited about the possibilities new drugs such as Ozempic could offer for renal patients

The Guardian - UK

‘Feels quite cruel’: Australians with ADHD scrambling to find medication amid shortage

Patient says pharmacists she went to were suspicious because Vyvanse is a stimulant, causing her the ‘most dehumanising medical experience’ of her life

The Guardian - AU

3 'Strong Buy'-Rated Stocks to Buy Now on the Dip

These outstanding growth stocks are worth buying on the dip.

Barchart

Health officials tell US doctors to be alert for dengue as cases ramp up worldwide

U.S. health officials are warning doctors to be alert for dengue cases as the tropical disease breaks international records

The Independent UK

UK swapped to fatal US blood products to save money, minutes suggest

Exclusive: contaminated blood campaigners say internal 1976 Immuno AG document proves British government negligence

The Guardian - UK

Hyderabad’s Biological E. to make 50 million doses of Takeda’s dengue vaccine

Takeda and Hyderabad-based vaccine maker Biological E. have formed a strategic partnership to accelerate access to the Japanese firm’s QDENGA dengue vaccine (TAK-003) multi-dose vials.

The Hindu

3 Outsourcing Stocks With Potential to Make Gains

The outsourcing sector is well-placed to thrive due to its ability to provide cost-effective solutions, access to specialized skills, focus on core business activities, and enhanced productivity. Therefore, it could be wise to invest in quality outsourcing stocks Cognizant (CTSH), Stride (LRN), and Barrett Business Services (BBSI) for substantial gains.…

StockNews.com

Get all your
news in one place.

100's of premium titles.
One news app.

The Hindu

Regulator issues alert over sale of falsified versions of 2 drugs

Drugs regulator Drugs Controller General of India has directed States and Union Territories to keep vigil on sale and distribution of falsified versions of two drugs, liver medication Defitelio and Takeda’s cancer drug Adcetris after alerts from World Health Organization

Fortune

Digitalization could be the answer to better health care for patients. But first, they need to trust it

Takeda Pharmaceutical chief digital trust officer Mike Towers says his industry has been slow to adapt, but is accelerating fast.

The Conversation

'The dirty disease' – both smokers and non-smokers get lung cancer. They face stigma on top of illness

Earlier this year, federal health minister Mark Butler announced a new national Lung Cancer Screening Program. The first of its kind for lung cancer, the screening program will open initially to current and former smokers aged 50 to 70 years by July 2025. It aims to save lives by detecting…

Daily Mirror

Dengue fever warning to Brits heading off to popular holiday resorts this summer

Brits planning to travel abroad are being warned about the risks of potentially deadly dengue fever - a disease spread by Asian tiger mosquitoes and which has been detected in the likes of Ibiza and southern France

Get all your
news in one place.

100's of premium titles.
One news app.

Businessweek

AI Drug Discovery Is a $50 Billion Opportunity for Big Pharma

Artificial intelligence can shave years off the development process, and companies like Japan’s Takeda are making large investments.

The Hindu

India urges G20 countries to collaborate, focus on evidence-based research

Ahead of the annual India-U.S. BioPharma and Healthcare Summit to be attended by scientists, academicians, corporate leaders, and officials from both countries, a top Indian official has urged the G20 countries to collaborate and focus on evidence-based research.

The Japan News/Yomiuri

Japan-made dengue vaccine to soon be marketed in Indonesia

A Japanese dengue vaccine will soon be marketed in Indonesia, where the mosquito-borne viral disease is endemic.

Tribune News Service

Bill of the Month: $38,398 for a single shot of a very old cancer drug

Dr. Josie Tenore and Paul Hinds were introduced by a mutual friend in 2017 and hadn’t been going out long when she laid down the law: He had to get a physical.

The Conversation

My snoring is waking up my partner. Apart from a CPAP machine, what are the options?

Snoring happens when the muscles and tissues that surround the upper airway (at the back of the nose to the throat region) vibrate during sleep. Snoring can disturb your bed partner’s sleep, and it can be a symptom of the most common sleep-related breathing disorder, obstructive sleep apnoea.

Chicago Sun-Times

For Highland Park man, why did a single shot of a very old cancer drug cost $38,398?

What’s behind the $38,398 price tag for a single dose of the drug to treat prostate cancer? A mixture of unrelenting drug price increases and hospital system consolidation.

WEKU

It cost $38,398 for a single shot of a very old cancer drug

Lupron, a drug patented half a century ago, treats advanced prostate cancer. It costs a few hundred dollars in the U.K. — so why are U.S. hospitals charging so much more to administer it?

1 2

People

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

the World Health Organization

Read news from The Economist, FT, and more,
with one subscription

Topics

Artificial Intelligence

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.